AUTL Overview

Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.

Wall Street analysts forecast AUTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUTL is7.18 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Autolus Therapeutics PLC revenue for the last quarter amounts to 26.22M USD, increased 191.89

Autolus Therapeutics PLC. EPS for the last quarter amounts to -0.27 USD, increased 3.85

Autolus Therapeutics PLC (AUTL) has 754 emplpoyees as of May 31 2026.

Today AUTL has the market capitalization of 497.71M USD.